News

Malaysia: Amendment Regulations 2025 [P.U. (A) 330] – Class A Change Payment Fee – October/November 2025

Malaysia: Amendment Regulations 2025 [P.U. (A) 330] – Class A Change Payment Fee – October/November 2025

  • 2025-11-21 08:14:15

The Malaysian Medical Device Authority (MDA) has issued the Medical Device (Amendment) Regulations 2025 [P.U.(A) 330], which were gazetted on 11 September 2025. This amendment revises the fee structure for registrations of Class A medical device effective on or after 1 January 2026. Stakeholders are advised to review the changes and plan their submissions accordingly to ensure timely compliance.

More
MALAYSIA : Updated in Harmonised Borderline Products in ASEAN (MDA/GD/0063) and Harmonised Classification of Medical Devices in ASEAN (MDA/GD/0062) – June/July 2025

MALAYSIA : Updated in Harmonised Borderline Products in ASEAN (MDA/GD/0063) and Harmonised Classification of Medical Devices in ASEAN (MDA/GD/0062) – June/July 2025

  • 2025-07-10 10:02:10

The Malaysia Medical Device Authority (MDA) has published the latest edition of Harmonised Borderline Products in ASEAN which provides an updated classifications list for products that may fall under medical device regulations across ASEAN member states. This update helps establishments to determine their products classification (medical device or non-medical device).

More
Thailand: FDA ANNOUNCEMENT ON GUIDELINES SUBJECT TO CLASS 2, 3, AND 4 TECHNICAL DOCUMENTS TRANSFER AND REFER IMPLEMENTATION – October/November 2024

Thailand: FDA ANNOUNCEMENT ON GUIDELINES SUBJECT TO CLASS 2, 3, AND 4 TECHNICAL DOCUMENTS TRANSFER AND REFER IMPLEMENTATION – October/November 2024

  • 2024-11-04 08:50:30

Thai FDA introduced new guidelines for handling the registration of medical devices under Notified (Class 2 & 3) and Licensed (Class 4) Medical Device. Thai FDA permitted referencing of previously approved dossiers when applying for brand name changes ("Refer") and for the transfer of medical device licenses between medical device establishment ("Transfer"). This move aimed to streamline the regulatory process, reduce redundant dossier reviews, and simplify licensing in Thailand's medical device sector.

More
THAILAND: GUIDELINE FOR EVALUATING DOCUMENTS FOR CLASS 2,3,4 MEDICAL DEVICES THROUGH CONCISE EVALUATION AND RELIANCE PROGRAM - APRIL/MAY 2024

THAILAND: GUIDELINE FOR EVALUATING DOCUMENTS FOR CLASS 2,3,4 MEDICAL DEVICES THROUGH CONCISE EVALUATION AND RELIANCE PROGRAM - APRIL/MAY 2024

  • 2024-05-07 08:47:38

Thai FDA has replaced its previous criteria for evaluating medical devices via expedited routes with new guidelines published in 2024. The aim is to streamline the evaluation process for Licensed and Notified medical devices (Class 2,3,4) while ensuring quality, efficiency, and safety. The announcement outlines criteria, documents required, and regulatory procedures for the Concise Evaluation and Reliance Program routes under expedited route review.

More
SINGAPORE: HSA IS RECOGNIZED BY WHO AS STRINGENT REGULATORY AUTHORITY (SRA) FOR CLASS C AND D IN VITRO DIAGNOSTIC MEDICAL DEVICES (IVD) - JULY/AUGUST 2023

SINGAPORE: HSA IS RECOGNIZED BY WHO AS STRINGENT REGULATORY AUTHORITY (SRA) FOR CLASS C AND D IN VITRO DIAGNOSTIC MEDICAL DEVICES (IVD) - JULY/AUGUST 2023

  • 2023-07-21 02:32:25

Singapore's Health Science Authority (HSA) is pleased to announce their status as a recognized Stringent Regulatory Authority (SRA) for Class C and D IVD by WHO. The SRA status means high-risk IVD products registered with HSA might obtain faster evaluation through WHO prequalification assessment, enabling manufacturers accelerated access to global markets.

More
SINGAPORE: Consultation on GN-14 Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices– June/July 2023

SINGAPORE: Consultation on GN-14 Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices– June/July 2023

  • 2023-06-28 07:35:36

HSA would like to consult the industry/stakeholders regarding updates and revisions of GN-14 Guidance on the Risk Classification of In Vitro Diagnostic Medical Devices (R3). The key update includes clarification notes on the classification of control materials and software, also clarifications to the risk classification rules 1-5. The consultation period is open from 2-30 May 2023 through email to HSA.

More